GEN Exclusives

More »

Feature Articles

More »
Feb 1, 2014 (Vol. 34, No. 3)

High-Content Analysis: The “Just Right” Solution

  • Click Image To Enlarge +
    High-content analysis (HCA) combines digital microscopy and flow cytometry. HCA can outperform either technology in many applications, and the integration of data-mining capabilities makes HCA even more powerful.

    The ever-expanding field of high-content analysis (HCA) continues to lure scientists from many disciplines. Because of its versatility, high-content screening can be used for many applications including basic research, target identification, primary screening, and predicting clinical outcomes. CHI’s upcoming “High-Content Analysis” meeting will include presentations on monitoring cellular changes in real time, conducting multiplexing assays via biological bar-coding, and measuring neurodegenerative changes resulting from the failure to clear biological debris.

    High-content analysis combines the strength of three proven tools, notes Scott Keefer, manager of product marketing for Thermo Fisher Scientific’s cellular imaging and analysis products. “The first is fluorescent microscopy that not only provides flexibility for reagent selection but also the ability to record and then measure cellular changes at different resolution levels. A second important tool is use of a plate reader. This easy-to-use automation allows high-capacity quantitation and keeps true to a multiwell or multisample format. The third tool harnesses the power of flow cytometry for multiparameter assessment of individual cell populations,” Keefer continues.

    “What is unique about a dedicated technology for high content rather than, for example, building a plate reader into a high-content machine, is the breadth and depth of applications that can be addressed. In other types of platforms, users have much less flexibility.”

    High-content screening follows a straightforward four-step process. First, cells are plated and treated with a compound of interest or siRNA designed to elicit a response. Second, cells are stained with fluorescent dyes that target desired subcellular organelles or proteins. Third, cells are imaged to extract data from cells and wells. Finally, data is mined to characterize phenotypes.

    High-content analysis is being utilized with increasing frequency in mainstream research, notes Keefer. “We are finding more use across the scale of complexity every day. Over 1,000 peer-reviewed publications through 2012, covering a breadth of studies such as neuronal regeneration, in vitro toxicology, proliferation, migration, and signaling, have been published with the variety of applications growing daily.”

    Pathologic angiogenesis is a hallmark of cancer and other inflammatory diseases. Ephrin receptor tyrosine kinase A2 (EphA2) has been identified as a potential target for inhibiting angiogenesis in malignancies. “We wanted to establish a high-throughput assay for screening leads that inhibit EphA2 function,” says Susanne Heynen-Genel, Ph.D., director, high-content screening systems, Conrad Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute.

    She, along with colleague Elena Pasquale, Ph.D., a professor at Stanford-Burnham’s NCI-designated cancer center and a participant in the institute’s tumor initiation and maintenance program, cancer center at the same institution, developed a phenotypic approach for high-content screening that was based on cell retraction/contraction in response to activation of EphA2 by binding of a recombinant form of its ligand, ephrin-A1 Fc.

    According to Dr. Heynen-Genel, “The assay we developed used a prostate cancer cell line, PC3, engineered with a membrane-targeted green-fluorescent protein (GFP). Cells were first adhered to microtiter wells and then preincubated with a compound library followed by addition of the ephrin ligand. We quantified cell retraction at different time points using the GFP fluorescence to outline the cell shapes.”

    Dr. Heynen-Genel says they first developed the assay in lower throughput and then transitioned it into the high-content arena. This was not without its challenges. “When extending the assay to higher throughput in 384-well plates, we found that a number of conditions needed to be more exactly optimized, such as concentration of ligand, temperature of incubation, and timing of maximum retraction. We also needed to better define extent of cell retraction. Our solution was to examine six or seven parameters instead of one. The multiparametric approach worked, but required more complex analysis.”

    Dr. Pasquale notes that these assays may provide more information than just comparison of lead compound activity. “EphA2 is widely expressed in tumor cell vasculature, but less so in normal cells. It isn’t clear how it works in cancer cells as related to migration, invasiveness, proliferation, and signaling pathways. These screens may reveal new mechanisms for how the receptor acts and suggest new approaches for targeting malignancies.”

  • Bar-Coding for Imaging

    Click Image To Enlarge +
    UCSF researchers developed a bar-coded nuclear reporter. Two cell lines, each expressing a different yellow fluorescent protein (FP)-linked reporter, are co-cultured. Cells in the mixture are identified by automated image analysis programs that define each cell nucleus marked with red FPs. Via different red FPs, the cell lines are distinguished by their characteristic ratios of red fluorescence in two different emission channels. Then the amounts of yellow fluorescence are assigned to the specific reporter associated with each bar-coded cell. [Source: Krylova et al. (2013) PloS ONE 8(5): e63286.]

    One of the major impediments to improving cell-screening capabilities centers on improving biological significance and clinical relevance. One way to enhance that process is to screen several biologically relevant assays in parallel, according to Fred Schaufele, Ph.D., associate professor, Center for Reproductive Sciences, University of California San Francisco.

    “We can generate much more biologically relevant assays using a combination of different assays, that is, by multiplexing. High-throughput, multichannel fluorescence microscopy allows quantification of multiple specific cellular subcompartments.”

    One problem with that approach, however, is that multiple fluorophores often overlap in their excitation and emission properties. “We developed a cellular bar-code technology of assay-specific markers consisting of distinct combinations of different ‘red’ fluorescent proteins coupled to a nuclear localization signal that combines multiple cell-based assays into one well. The bar-code markers are excited by a common wavelength of light, then distinguished due to their different relative fluorescence in two emission channels. This allows us to link different reporters to different bar-code-marked cells and to realize multiple reporter outputs from a single well in a drug screening campaign.”

    “A small start-up, XCellAssay, has been created with the goal of realizing up to 56 different marker/reporter combinations, although we have, to date, established the methodology with just three reporters.”

    Dr. Schaufele’s laboratory studies the androgen receptor and prostate cancer. Most prostate tumors are dependent upon androgens for survival and proliferation. Thus, the androgen receptor is a prime target for intervention, particularly the lowering of androgens by competitive inhibition. “The goal of treatment is to selectively modulate the androgen receptor by activating or inhibiting only certain pathways. The bar code enables us to search for compound leads that fall into different activity classes, based upon their activity profiles at distinct androgen receptor functions.”

    According to Dr. Schaufele, with the ever-increasing costs of drug development, the ability to identify a highly specific drug candidate across multiple assays can greatly reduce the cost of post-screening therapeutic workups while enabling the rapid definition of drug leads likely to have the least disruptive off-target effects. The multiplexing abilities also “bin” hits into similar or different activity profiles across the multiple assay readouts to define distinct functional classes of hits. Dr. Schaufele suspects this ability will minimize the waste of time, effort, and money that occurs when similar leads are unknowingly worked up in costly studies when other, potentially more relevant leads in other activity classes could have been examined.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »